Published

Exploring the therapeutic potential of psychedelics: Fear extinction mechanisms and amygdala modulation.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Psychedelics
Date: 2025-01-01
Source: PubMed
DOI: 10.61373/pp024b.0019
PubMed: 42440716

Authors

Kelly TJ Liu QS

Watch author

Derived topics and classifications

psilocybin psilocin PTSD Pharmacology Mechanism of Action Receptor Pharmacology Clinical Trial Animal Study Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled TrialClinicalTrials.gov · 2026-07-14 PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10 PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10 Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2026-06-25 Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerClinicalTrials.gov · 2026-08-05 Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)ClinicalTrials.gov · 2026-07-30 Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialClinicalTrials.gov · 2026-07-28 Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-09